Dr Reddys Laboratories Ltd 6-K, filed May 20, 2022
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on May 20, 2022.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2022
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
|
Exhibit |
Description of Exhibits | |
| 99.2 | Intimation dated May 19, 2022 titled Outcome of Board Meeting held on May 19, 2022 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) |
|||
| Date: May 19, 2022 | By: | /s/ K Randhir Singh | |
| Name: K Randhir Singh | |||
| Title: Company Secretary | |||
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
May 19, 2022
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd.
Dear Sir/Madam,
Sub: Outcome of Board Meeting held on May 19, 2022
In furtherance to our letter dated March 29, 2022, we would like to inform you that the Board of Directors of the Company at their meeting held on May 19, 2022, has, inter alia, transacted the following businesses:
Financial Results
| A. | Approved the Audited Financial Results of the Company for the quarter and year ended March 31, 2022. |
In terms of the above, we are enclosing herewith the following:
| 1. | Audited Consolidated Financial Results of the Company and its subsidiaries for the quarter and year ended March 31, 2022 as per International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB). |
| 2. | Press Release on Financial Results of the Company for the above period. |
| 3. | Audited Consolidated Financial Results of the Company and its subsidiaries for the quarter and year ended March 31, 2022 as per Indian Accounting Standards. |
| 4. | Audited Standalone Financial Results of the Company for the quarter and year ended March 31, 2022 as per Indian Accounting Standards. |
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audit Report of the Statutory Auditors on the financial results as mentioned at serial nos. 3 & 4 are also enclosed.
We would like to confirm that the Statutory Auditors of the Company, have issued Audit Reports with 'Unmodified Opinion' on the Audited Financial Statements of the Company (Standalone and Consolidated) for the year ended March 31, 2022.
 |
Dividend
| B. | Recommended a final dividend of Rs.30/- (600%) per equity share of Rs. 5/- each for the financial year 2021-22. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the 38th Annual General Meeting (AGM). |
The Board Meeting commenced at 10.15 AM and concluded at 12.28 PM.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
| /s/ K Randhir Singh | ||
| K Randhir Singh | ||
| Company Secretary & Compliance Officer |
Encl: As above
